Answers are grounded in this paper and cite their sources.
Rho (D) immune globulin intravenous (IV RhIG, WinRho SDF) has been shown to be a safe treatment for idiopathic thrombocytopenic purpura. Common side effects of IV RhIG include mild hemolysis, febrile reaction and headache. Significant hemolysis with renal impairment is infrequently noted. A single case of irreversible encephalopathy following IV RhIG has been reported. We report a second case of encephalopathy following an infusion of IV RhIG for treatment of idiopathic thrombocytopenic purpura.
No takes yet. Share an insight, caveat, or question.
Golla et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: